A new treatment for eye disease is designed to bind all forms of Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PLGF) proteins which play a part in the abnormal growth of new blood vessels. [caption id="attachment_1020" align="alignleft" width="150"] VEGF Trap-Eye[/caption] This new treatment, VEGF Trap-Eye is being developed by Regeneron and Bayer HealthCare. Two trials are under way to compare treatment? of wet Age-Related Macular Degeneration (AMD) with VEGF Trap-Eye and Lucentis?. In addition, VEGF Trap-Eye is being evaluated as a treatment for Central Retinal Vein Occlusion (CRVO) and Diabetic Macular Edema (DME). VEGF Trap-Eye is administered locally and is specifically purified and formulated for intravitreal administration. It is hoped that by counteracting the effects of VEGF-A and PLGF, VEGF-Trap Eye will prove to be a beneficial therapy for those suffering from these eye disorders.* Andrea Schumann Staff Writer
The latest retinal eye treatment is a TRAP!
- by Dr. Paul Krawitz
- 04 May, 2010